These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 39192804)
21. Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein. Ishimaru H; Nishimura M; Shigematsu H; Marini MI; Hasegawa N; Takamiya R; Iwata S; Mori Y J Virol; 2024 May; 98(5):e0041624. PubMed ID: 38624232 [TBL] [Abstract][Full Text] [Related]
22. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD Elife; 2020 Oct; 9():. PubMed ID: 33112236 [TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349 [TBL] [Abstract][Full Text] [Related]
24. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron. Wang L; Møhlenberg M; Wang P; Zhou H Cytokine Growth Factor Rev; 2023 Apr; 70():13-25. PubMed ID: 36948931 [TBL] [Abstract][Full Text] [Related]
26. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies. He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739 [TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. McCallum M; Bassi J; De Marco A; Chen A; Walls AC; Di Iulio J; Tortorici MA; Navarro MJ; Silacci-Fregni C; Saliba C; Sprouse KR; Agostini M; Pinto D; Culap K; Bianchi S; Jaconi S; Cameroni E; Bowen JE; Tilles SW; Pizzuto MS; Guastalla SB; Bona G; Pellanda AF; Garzoni C; Van Voorhis WC; Rosen LE; Snell G; Telenti A; Virgin HW; Piccoli L; Corti D; Veesler D Science; 2021 Aug; 373(6555):648-654. PubMed ID: 34210893 [TBL] [Abstract][Full Text] [Related]
28. Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster. Favresse J; Gillot C; Cabo J; David C; Dogné JM; Douxfils J Int J Infect Dis; 2024 Jun; 143():107028. PubMed ID: 38583825 [TBL] [Abstract][Full Text] [Related]
29. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668 [TBL] [Abstract][Full Text] [Related]
30. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines. Chalkias S; McGhee N; Whatley JL; Essink B; Brosz A; Tomassini JE; Girard B; Edwards DK; Wu K; Nasir A; Lee D; Avena LE; Feng J; Deng W; Montefiori DC; Baden LR; Miller JM; Das R J Infect Dis; 2024 Aug; 230(2):e279-e286. PubMed ID: 38349280 [TBL] [Abstract][Full Text] [Related]
31. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Wang X; Zhao X; Song J; Wu J; Zhu Y; Li M; Cui Y; Chen Y; Yang L; Liu J; Zhu H; Jiang S; Wang P Emerg Microbes Infect; 2022 Dec; 11(1):477-481. PubMed ID: 35034583 [TBL] [Abstract][Full Text] [Related]
32. The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine. Chen X; Mohapatra A; Nguyen HTV; Schimanski L; Kit Tan T; Rijal P; Chen CP; Cheng SH; Lee WH; Chou YC; Townsend AR; Ma C; Huang KA PLoS Pathog; 2024 Jun; 20(6):e1012246. PubMed ID: 38857264 [TBL] [Abstract][Full Text] [Related]
33. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein. Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430 [TBL] [Abstract][Full Text] [Related]
34. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456 [TBL] [Abstract][Full Text] [Related]
35. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cerutti G; Guo Y; Zhou T; Gorman J; Lee M; Rapp M; Reddem ER; Yu J; Bahna F; Bimela J; Huang Y; Katsamba PS; Liu L; Nair MS; Rawi R; Olia AS; Wang P; Zhang B; Chuang GY; Ho DD; Sheng Z; Kwong PD; Shapiro L Cell Host Microbe; 2021 May; 29(5):819-833.e7. PubMed ID: 33789084 [TBL] [Abstract][Full Text] [Related]
36. Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model. Wongnak R; Brindha S; Oba M; Yoshizue T; Islam MD; Islam MM; Takemae H; Mizutani T; Kuroda Y Molecules; 2024 Jun; 29(11):. PubMed ID: 38893549 [TBL] [Abstract][Full Text] [Related]